- Home
- IPHA vs PBYI Comparison
IPHA vs PBYI Comparison
Compare IPHA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | PBYI |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 263.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IPHA | PBYI |
|---|---|---|
| Price | $1.71 | $5.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.00 | ★ $7.00 |
| AVG Volume (30 Days) | 25.6K | ★ 393.2K |
| Earning Date | 09-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $14,839,695.00 | ★ $211,995,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | ★ N/A | $7.94 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $2.58 |
| 52 Week High | $2.63 | $6.12 |
Technical Indicators
Market Signals| Indicator | IPHA | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 66.14 |
| Support Level | $1.64 | $5.51 |
| Resistance Level | $1.81 | $5.73 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 18.75 | 95.76 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.